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Znaczenie wiązań disiarczkowych w ludzkim hormonie wzrostu
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Abstract
Growth hormone (GH) structure is stabilised by two disulphide bonds, C53-C165 and C182-C189 in human GH. Researchers have inves-
tigated the role of these structural features since the late 1960s. Early studies implied that the disulphide bonds would not be important 
for biological activity of GH. However, more advanced techniques, as well as clues from patients carrying mutations in their GH1 gene, 
have demonstrated that the integrity of the disulphide bond between cysteines C53 and C165 is required for biological activity of GH. 
In contrast, disruption of the C-terminal disulphide bond (C182-C189) has only modest effects on the biological potency of GH, despite 
decreased binding affinity to GH receptor and reduced stability as shown by a comprehensive in vitro study. 
To confirm these results, we generated transgenic mice that express a human GH analogue, C189A, and observed normal growth-promoting 
and lipolytic activities. In this article, we present new data and review old results concerning the disulphide bonds of GH. We also discuss 
relevant mutations found in patients with growth disorders. (Endokrynol Pol 2013; 64 (4): 300–304)
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Streszczenie
Struktura hormonu wzrostu (GH, growth hormone) stabilizowana jest dwoma wiązaniami disiarczkowymi — C53-C165 o C182-C189 
w ludzkim GH. Naukowcy badają rolę tych cech strukturalnych od końca lat 60. ubiegłego stulecia. Początkowe badania sugerowały, że 
wspomniane wiązania disiarczkowe nie są istotne dla aktywności biologicznej GH. Jednak w wyniku zastosowania bardziej zaawansowa-
nych technik badawczych, a także na podstawie danych uzyskanych u pacjentów będących nosicielami mutacji genu GH1 stwierdzono, 
że dla aktywności biologicznej GH konieczna jest obecność wiązania disiarczkowego między cysteiną w pozycji C53 i cysteiną w pozycji 
C165. Z kolei przerwanie C-końcowego wiązania disiarczkowego (C182-C189) w niewielkim zakresie wpływa na siłę działania biologicznego 
GH mimo stwierdzonego w kompleksowym badaniu in vitro obniżenia powinowactwa wiązania z receptorem GH i obniżenia trwałości. 
W celu potwierdzenia tych wyników autorzy otrzymali myszy transgeniczne, u których zachodzi ekspresja analogu ludzkiego GH — 
C189A, i stwierdzili prawidłowe działanie pobudzające wzrost i prawidłowy wpływ na lipolizę. W niniejszej pracy przedstawiamy nowe 
dane i przegląd dotychczasowych danych na temat wiązań disiarczkowych w GH. Omawiany też istotne mutacje stwierdzane u pacjentów 
z zaburzeniami wzrastania. (Endokrynol Pol 2013; 64 (4): 300–304)
Słowa kluczowe: hormon wzrostu, disiarczki, związek pomiędzy strukturą i aktywnością
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Introduction
Knowledge about the structure-function relation-
ships of growth hormone (GH) helps to understand 
how a specific gene mutation could be associated with 
a patient’s phenotype. The overall structure of GH is 
stabilised by two disulphide bonds that are conserved 
across species. Corresponding disulphide bonds are 
also found in other members of the GH family. Mu-
tations identified in patients with retarded growth 
as well as a handful of in vitro and in vivo studies 
have helped to establish the role of these disulphide 
bonds in normal GH action. Issues associated with 
GH’s disulphide bonds as they relate to GH action 
are described below. 
GH structure
A GH molecule consists of four alpha-helices that are 
organised in an up-up-down-down manner [1]. The GH 
structure is stabilised by two disulphide bonds; C53-
C165 links the crossover connection between helices I 
and II to helix IV, and C182-C189 forms a small loop in 
the C-terminus (Fig. 1) [2]. GH binds to a pre-dimerised 
GH receptor (GHR) via two binding sites: a high-affinity 
binding site 1 and a low-affinity binding site 2 [1, 3]. 
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The C-terminal disulphide bond is involved in site 
1 binding, whereas C53-C165 is not in close proximity 
to either binding site [4].
Disulphide bonds
Disulphide bonds, or simply disulphides, are formed be-
tween two cysteine molecules through oxidation of their 
thiol groups. In eukaryotic cells, the endoplasmic reticu-
lum (ER) is the main site for disulphide bond formation, 
but this reaction also occurs in the mitochondria [5]. Di-
sulphide bonds can be formed spontaneously but, in vivo, 
the reaction is usually catalysed by enzymes, such as the 
protein disulphide isomerases in the ER [6, 7]. Disulphide 
bonds are important stabilisers of a protein’s structure but 
they also have a role in facilitating protein folding [6, 7].
The GH family
The two disulphide bonds found in GH are conserved 
across species and also present in other members of the 
GH family. The GH gene cluster on chromosome 17 
in humans contains genes for the ‘normal’, pituitary- 
-derived GH (GH1 or GH-N), the placental GH variant (GH2 
or GH-V) and three placental lactogens (PL); CS-A and 
CS-B (or CSH1 and CSH2) encode the same polypeptide 
whereas the product of CS-L, a shorter variant, has not 
been detected on protein level [8,9]. The gene encoding 
prolactin (PRL), another member of the GH family, is 
located on chromosome 6 in humans. PRL gene diverged 
from the other GH family genes ~400 million years ago 
[10], and the mature protein shares 24% amino acid se-
quence identity with GH [11]. Genes of the GH cluster 
diverged ~10 million years ago [10]. Placental GH shares 
93% and PL 86% amino acid sequence identity with pi-
tuitary GH [11]. For comparison, cow and man diverged 
~75 million years ago [12] and they are 66% identical in 
their amino acid sequence [11]. All the aforementioned 
proteins contain two disulphide bonds similar to those 
in human GH [13–16]. PRL, the most distant relative, has 
an additional disulphide bond in its N-terminus [15].
Clinical significance
Heterozygous deletion of exon 3 of the GH1 gene, which 
leads to deletion of amino acids 32–71, causes isolated 
GH deficiency type II and subsequent short stature. 
The dominant negative effect is due to impaired GH 
secretion caused by the truncated GH [17]. Deletion 
of exon 3 disrupts the disulphide bond between C53-
C165 and leaves an ‘unpaired’ cysteine. However, since 
another GH1 mutation, C53S, does not display a domi-
nant negative effect, it is not likely that the unpaired 
C165 would be responsible for the defective secretion. 
C53S causes short stature only in the homozygous state 
and is found in circulation at rather high levels (basal 
13.5 ng/mL, peak after ITT 44.7 ng/mL) [18]. In vitro stud-
ies regarding exon 3 deletion and the C53S analogue 
are discussed in the following section.
Mutations that alter the C-terminal disulphide 
bond are less common. A C182R substitution has been 
reported in a patient with hypertension in a study 
that also found an inverse correlation between adult 
height and central hypertension [19]. Unfortunately, 
the height of the patient carrying the C182R mutation 
was not reported. In a recent meeting of the GH and 
IGF-1 research societies (Munich, Germany, 2012), 
a heterozygous deletion mutation that results in disrup-
tion of the C-terminal disulphide bond was reported to 
be associated with short stature, but the case report has 
not yet been published. In addition to the mutations 
that disrupt the disulphide bonds of GH, a few muta-
tions that introduce a fifth cysteine have been reported 
in patients with short stature [20, 21]. Such mutations 
could interfere with formation of native disulphide 
bonds or lead to intermolecular disulphide bonding. 
Free cysteines could also affect protein stability.
Figure 1. Location of disulphide bonds in a GH molecule. Protein 
Data Bank entry 1HGU [2] was modelled with RasMol Version 
2.4.7.2 (RasWin Molecular Graphics). Helices I, II, III, and IV as 
well as position of disulphide bonds are indicated 
Rycina 1. Umiejscowienie wiązań disiarczkowych w cząsteczce 
GH. Hasło „1HGU” zawarte w Protein Data Bank [2] poddano 
modelowaniu z użyciem programu RasMol w wersji 2.4.7.2 
(RasWin Molecular Graphics). Na rycinie wskazano helisy I, II, 
III i IV oraz pozycję wiązań disiarczkowych
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Early research 
Several papers described the significance of the GH’s 
disulphide bonds even before publication of the GH 
cDNA sequence, production of recombinant GH or 
determination of its crystal structure. In 1966, it was 
reported that human pituitary GH, when exposed to 
a rather harsh reduction and alkylation process using 
urea, mercaptoethanol, methylamine and iodoaceta-
mide, still retained most of GH’s action [22]. Biologi-
cal activity of the modified GH was examined by rat 
tibia (diameter) and pigeon crop sac growth tests. The 
authors reported that the reduced and alkylated GH 
retained full potency, although a trend of lower bioac-
tivity was seen in the pigeon crop sac test [22]. In a 1969 
report, the use of dithiothreitol allowed a more gentle 
reduction of disulphide bonds without a denaturant 
[23]. After reduction, GH was either carboxymethylated 
(CXY-GH) or carbamidomethylated (CAM-GH). CXY-
GH exhibited reduced biological activity in both the 
rat tibia and pigeon crop sac tests, whereas bioactivity 
of CAM-GH was unchanged. CXY-GH was also much 
more susceptible to trypsin digestion. The low stability 
of GH under these conditions explained the reduced 
bioactivity, and the authors concluded that disulphide 
bonds do not otherwise contribute to the biological 
activity of GH [23]. Additionally, CAM-GH was tested 
in GH-deficient prepubertal males and found to induce 
the same metabolic changes as unmodified GH [24]. 
Later structure-function studies showed that, com-
pared to native GH, both CAM-GH and CXY-GH have 
reduced immunoreactivity in radioimmunoassay as 
well as lower binding affinity to GHR using a radio-
receptor assay. However, their conformation did not 
differ from unmodified GH when analysed by circular 
dichroism spectrum [25]. 
Graf et al. were the first to specifically investigate 
the C-terminal disulphide bond [26]. They selectively 
reduced and alkylated either both GH disulphide bonds 
or only the C-terminal one. C-terminally carboxymeth-
ylated GH showed the same biological activity in rat 
tibia and pigeon crop sac tests as unaltered GH, whereas 
the fully carboxymethylated GH displayed decreased 
activity in both tests – in accordance with the studies 
using CXY-GH described above [23, 25, 26]. 
Site-directed mutagenesis
Advances in biotechnology have allowed manipulations 
at the DNA level such that chemical modifications are 
no longer needed for disruption of disulphide bonds. 
A C165A mutation was introduced into GH, disrupting 
the disulphide bond between C53 and C165 [27]. This 
GH analogue was expressed in E. coli at levels equal to 
wildtype (wt) GH (measured by radioimmunoassay) 
and displayed a similar digestion pattern with human 
plasmin enzyme, indicating a similar tertiary structure. 
Treatment of hypophysectomised rats with the GH-
C165A analogue had the same effect on growth as wt 
GH [27]. Another study analysed a wider variety of GH 
analogues: C53A, C53A+C165A, C53A+C165S, C165S 
and C165A [28]. They were expressed in E. coli and their 
bioactivity was determined by effect on differentiation 
of 3T3-F442A cells into adipocytes. Binding affinity to 
GHR was assessed by radioreceptor assay. The biologi-
cal activity of all the GH analogues was decreased, and 
the differences to wt GH did not seem to depend on the 
number of cysteines mutated or whether the cysteine 
was replaced with serine or alanine. Binding affinity 
of the GH analogues was approximately half of that of 
the wt GH [28].
In order to investigate differences in the roles of 
the two disulphide bonds of GH, cysteines of bovine 
GH (bGH) were replaced with serines, generating bGH 
analogues C53S, C164S, C53S+C164S, C181S, C189S 
and C181S+C189S [29]. Previous studies concerning 
the disulphide bonds in GH had been conducted in hu-
man GH, thus it was also of interest to find differences 
between bovine and human GH. Expression of the 
bGH analogues in mouse L-cells showed that the dis-
ruption of the disulphide bond between C53 and C164 
resulted in drastically decreased GH secretion. Also 
C181S+C189S showed reduced secretion but C181S 
and C189S analogues were secreted normally. These 
two analogues were further studied in regard to bind-
ing affinity to GHR. Both analogues displayed reduced 
binding affinity, but the change was much more promi-
nent for C181S [29]. A previous study had shown that 
a C182A mutation reduces receptor binding affinity of 
human GH. C189A could not be analysed in that study 
due to low production in E. coli [30]. Several bovine GH 
analogues were also expressed in transgenic mice [29]. 
Growth of mice expressing C53S, C53S+C189S, C164S 
and C164S+C181S did not differ from that of non-
transgenic mice, indicating that these analogues lack 
biological activity. On the other hand, mice expressing 
C181S or C189S analogues showed similar enhanced 
growth as mice expressing wt bGH [29].
The new millennium
In order to bring understanding to the dominant nega-
tive effect seen in patients with mutations that cause 
skipping of GH1 exon 3 (aa 32–71), Iliev et al. [31] deleted 
different fractions of exon 3 and performed site-directed 
mutagenesis to disrupt the disulphide bond between 
C53 and C165. Co-secretion with wt GH was studied 
in somatotroph-derived rat GH4C1 cells. The authors 
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concluded that the mutations that only affected the 
C53-C165 disulphide bond were not sufficient to impair 
secretion, although a minor inhibitory effect on wt GH 
secretion was observed. Size of the deletion was a more 
important factor [31].
Following the identification of the homozygous 
C53S mutation in a patient with short stature, Besson 
et al. characterised this GH analogue in vitro [18]. The 
GH analogue was expressed in Chinese hamster ovary 
cells, after which it was characterised regarding binding 
affinity and ability to activate the Jak/STAT pathway, the 
major signalling cascade activated by GH. An immu-
nofunctional assay that measures the integrity of both 
receptor binding sites [32] showed that the binding sites 
of GH analogue C53S were barely functional. Also, re-
sults from radioreceptor assay indicated a significantly 
reduced binding affinity to GHR. Consequently, this GH 
analogue also displayed a decreased bioactivity [18].
Motivated by a human mutation affecting the C-
terminal disulphide bond [unpublished data], Junnila 
et al. [11] performed an array of in vitro experiments in 
order to more closely characterise the importance of 
the C182-C189 disulphide bond. GH analogues C182A, 
C189A and C182A+C189A were expressed in human 
embryonic kidney cells. All GH analogues showed 
a significantly decreased GHR binding affinity, but only 
the C189A analogue also displayed a reduced biological 
activity in a cell proliferation assay compared to wt GH. 
C182A and C189A induced less STAT5 activation than 
wt and showed decreased stability. C182A+C189A was 
most similar to wt GH, indicating that a free cysteine af-
fects GH activity more than the absence of its C-terminal 
disulphide bond [11]. 
As a follow-up to the aforementioned study, 
transgenic mice expressing the human GH analogue 
C189A — the one with lowest binding affinity and 
bioactivity — were generated. These mice display 
a ‘giant’ phenotype (see Fig. 2) similarly to the mice 
expressing bGH C189S [29]. Body composition of 
transgenic mice expressing human GH analogue 
C189A (Fig. 3) resembles that of wt bGH transgenic 
mice: increased lean mass combined with a reduced 
fat mass [33]. Thus, despite the decrease in bioactivity 
seen in vitro, these mice show that the GH analogue 
C189A has high potency to induce growth and to 
mediate lipolytic effects in vivo.
Conclusions
Studies since the 1960s have attempted to elucidate 
the significance of GH’s disulphide bonds as it relates 
to the biological actions of GH. Early studies may have 
suffered from the harsh chemical treatments required 
for reduction of the disulphide bonds; yet, biological 
Figure 2. Female wt (left) and GH C189A transgenic littermate 
(right) at ten months of age. At this age, weight of the transgenic 
mouse was 48 g and that of the wt mouse 36 g
Rycina 2. Samica myszy dzikiego typu (po lewej) i pochodząca 
z tego samego miotu mysz transgeniczna GH C189A (po prawej) 
w wieku 10 miesięcy. W tym wieku masa ciała myszy transgenicznej 
wynosiła 48 g, a myszy dzikiego typu 36 g
Figure 3. Body composition of ten-month-old GH C189A 
transgenic (tg) mouse vs. wt mouse
Rycina 3. Skład ciała 10-miesięcznej myszy transgenicznej GH 
C189A (TG) i myszy typu dzikiego (WT)
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potency remained unchanged. This could be due to 
difficulties in achieving complete reduction of the disul-
phide bonds. Also, the tests for biological potency were 
not as sophisticated as they are today. The early stud-
ies did show that the disulphide bonds are important 
for protein stability, and the least stable forms of GH 
also displayed lower biological activity than intact GH 
[23]. A recent in vitro study focusing on the C-terminal 
disulphide bond observed a small decrease in biological 
activity despite loss of stability due to C182A or C189A 
mutations. Substituting both cysteines with alanines, 
generating GH analogue C182A+C189A, returned 
the stability to a normal level [11]. This indicates that 
the decreased stability is due to the unpaired cysteine 
and not absence of the C-terminal disulphide bond. 
To confirm this hypothesis, it would be of interest to 
perform similar tests with the disulphide bond between 
C53 and C165.
Transgenic mice that express human GH analogue 
C189A display a giant and lean phenotype – similar to 
mice expressing wt bovine GH. These mice provide 
further evidence that human GH with a disrupted C-
terminal disulphide bond has full biological potency. 
This is somewhat surprising since the mutation changes 
the conformation at the high-affinity binding site 1 and 
the GH analogue C189A had shown reduced binding 
affinity to GHR and decreased biological activity in in 
vitro studies. 
In summary, integrity of the C-terminal disulphide 
bond (C182-C189) is required for optimal binding to 
GHR and for normal stability, but not for biological 
activity. In contrast, the disulphide bond between C53 
and C165 is necessary for full biological activity of the 
hormone, indicating that it is more than a merely sup-
porting structure. 
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